Iveric bio: Building Momentum Around Zimura, Rate Buy

Dec. 07, 2022 1:26 AM ETIVERIC bio, Inc. (ISEE)COO1 Comment
Zach Bristow profile picture
Zach Bristow


  • Recent developments on Zimura label improve investor attractiveness.
  • Market for underlying treatments continues to grow with ageing population.
  • Here we've done a deep dive into the market opportunity and covered each of the respective treatment segments.
  • Rate buy, price objective $36.5.
Diabetic retinopathy (diabetic eye) . Spots floating in the vision, blurred vision, blindness. A complication of diabetes.

Tunatura/iStock via Getty Images

Investment Summary

Here at HBI, we've been actively uncovering selective opportunities within the broad healthcare biosphere. There are now numerous growth companies offering potential remedial breakthroughs in an otherwise complex disease segment. Within the domain, we've also positioned along the value chain for eye

This article was written by

Zach Bristow profile picture
Buy side equity portfolio strategist serving mandates throughout EU/US/APAC. Helping you position your portfolios for the future is my top priority. Shoot me a message to discuss trade ides or talk portfolio construction. Disclaimer:The opinions expressed in all articles do not constitute as investment advice. Please remember to conduct your own due diligence.

Disclosure: I/we have a beneficial long position in the shares of ISEE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.